John Eckfeldt, MD, PhD

Professor Emeritus, Department of Laboratory Medicine and Pathology

John Eckfeldt

Contact Info

eckfe001@umn.edu

Office Phone 612-626-3176

Fax 612-626-2696

Mailing Address:
MMC 609 Mayo
8609
420 Delaware SE
Minneapolis, MN 55455

University of Pennsylvania, Philadelphia, 1976

University of Minnesota (Clinical and Chemical Pathology), 1978

PhD, University of Pennsylvania, Philadelphia (Biophysics), 1975

MS, Cornell University (Physical Chemistry), 1969

BS, University of Pennsylvania, Philadelphia (Chemistry), 1967

Summary

Dr. Eckfeldt is a faculty investigator in the Advanced Research and Diagnostics Laboratory (ARDL), which provides central laboratory testing services for large, NIH-funded multi-center clinical trials. Through numerous national studies he has established himself as a leading researcher in the area of cardiovascular disease epidemiology, particularly the role lipids and other biomarkers play in cardiovascular diseases. Eckfeldt was principal laboratory investigator for the Hispanic Community Health Study, an NIH-funded multicenter epidemiologic study of U.S. Hispanic/Latino populations, and is the PI for the ancillary Hispanic Community Children's Health Study / Study of Latino Youth (SOL Youth), a multicenter study of Hispanic/Latino children living in the U.S. The SOL Youth study is designed to disclose the prevalence and distribution of obesity-promoting lifestyle behaviors, cardio-metabolic risk profiles, and novel biomarkers associated with obesity and insulin resistance.

In recent years Eckfeldt has focused mainly on kidney disease. He is a co-investigator with the Chronic Kidney Disease Biomarkers Consortium (CKD-BioCon). CKD-BioCON is a longitudinal study involving multiple universities with NIH’s National Institute of Diabetes and Digestive and Kidney Diseases that seeks to discover, develop, validate and qualify biomarkers based on biosamples from well-characterized CKD patients. He also serves as co-PI for the Preventing Early Renal Loss in Diabetes (PERL) consortium. The consortium has undertaken a multi-center, double-blind, placebo-controlled, randomized clinical trial aimed at evaluating the efficacy of allopurinol in preventing kidney function loss in individuals with type 1 diabetes. In addition, Eckfeldt is a co-investigator and the central laboratory director in the chronic kidney disease epidemiology collaboration (CKD-EPI). In this capacity he tests protein biomarkers such as cystatin C, an important marker for measuring the glomerular filtration rate, which indicates how well the kidneys are working.

Dr. Eckfeldt has long had an interest in assuring the reliability and long-term stability of assay results in large-scale epidemiological observational and interventional research studies. In addition he has sought to further the standardization and harmonization of clinical laboratories and inter-laboratory comparability through committee work at the College of American Pathologists (CAP) and working group participation at the International Standards Organization (ISO).

Professional Associations

  • American Association for Clinical Chemistry, 1978 - present
  • Academy Academy of Clinical Laboratory Physicians and Scientists, 1979 - present
  • Minnesota Society of Pathologists, 1979 - present
  • Minnesota Department of Health Ad Hoc Technical Advisory Committee on Newborn Screening,
    Chair 1993 - 1996 and member 2004 - present
  • Sigma Xi, 1980 - present
  • College of American Pathologists, 1981 - present
  • American Medical Association, 1985 - present
  • Minnesota Medical Association, 1985 - present
  • Hennepin County Medical Association, 1985 - present
  • American Society for Human Genetics, 1995 - present

Research

Publications

PubMed

  • Seegmiller JC, Eckfeldt JH, Lieske JC. Challenges in Measuring Glomerular Filtration Rate: A Clinical Laboratory Perspective. Adv Chronic Kidney Dis. 2018 Jan;25(1):84-92. doi: 10.1053/j.ackd.2017.10.006
  • Schwartz GJ, Wang H, Erway B, Nordin G, Seegmiller J, Lieske JX, Bäck S-E, Miller WG, Eckfeldt JH. Multicenter Laboratory Comparison of Iohexol Measurement. The Journal of Applied Laboratory Medicine Mar 2018, 2 (5) 711-724; DOI: 10.1373/jalm.2017.024240 http://jalm.aaccjnls.org/content/2/5/711
  • Karger AB, Inker LA, Coresh J, Levey AS, Eckfeldt JH. Novel Filtration Markers for GFR Estimation. EJIFCC 2017 Dec 19:28(4):277-288.eCollection 2017 Dec. https://www.ncbi.nlm.nih.gov/pubmed/29333147
  • Eckfeldt JH, Karger AB, Miller WG, Rynders GP, Inker LA. Performance in measurement of serum cystatin C by laboratories participating in the college of american pathologists 2014 CYS survey. Arch Pathol Lab Med 2015;139:888-893.
  • Folsom, Aaron R.; Alonso, Álvaro Alonso; Misialek, Jeffrey R.; Michos, Erin D.; Selvin, Elizabeth; Eckfeldt, John H.; Coresh, Josef; Pankow, James S.; Lutsey, Pamela L. Parathyroid hormone concentration and risk of cardiovascular diseases: The Atherosclerosis Risk in Communities (ARIC) study. American Heart Journal 2014
  • Sørensen, Izel F.; Vázquez, Ana I.; Irvin, Marguerite Ryan; Sørensen, Peter; Davis, Barry R.; Ford, Charles E.; Boerwinkle, Eric Eric; Eckfeldt, John H.; Arnett, Donna K. Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study. Pharmacogenetics and Genomics. 2014
  • Novel filtration markers as predictors of all-cause and cardiovascular mortality in US adults. Foster MC; Inker LA; Levey AS; Selvin E; Eckfeldt J; Juraschek SP; Coresh J; CKD Biomarkers Consortium. American Journal of Kidney Diseases. 62(1):42-51, 2013 Jul.
    [Journal Article. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov't]
    UI: 23518194
  • Estimating glomerular filtration rate from serum creatinine and cystatin C.[Erratum appears in N Engl J Med. 2012 Nov 22;367(21):2060], [Erratum appears in N Engl J Med. 2012 Aug 16;367(7):681] Inker LA; Schmid CH; Tighiouart H; Eckfeldt JH; Feldman HI; Greene T; Kusek JW; Manzi J; Van Lente F; Zhang YL; Coresh J; Levey AS; CKD-EPI Investigators. New England Journal of Medicine. 367(1):20-9, 2012 Jul 5.
  • Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Alderman MH; Piller LB; Ford CE; Probstfield JL; Oparil S; Cushman WC; Einhorn PT; Franklin SS; Papademetriou V; Ong ST; Eckfeldt JH; Furberg CD; Calhoun DA; Davis BR; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Hypertension. 59(5):926-33, 2012 May.
  • Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study. Lynch AI; Eckfeldt JH; Davis BR; Ford CE; Boerwinkle E; Leiendecker-Foster C; Arnett DK. Pharmacogenetics and Genomics. 22(5):355-66, 2012 May.

Clinical

Board Certifications

Clinical and Chemical Pathology, Clinical Chemistry